Qilu Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 1992-08-21
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.qilu-pharma.com
Clinical Trials
165
Active:23
Completed:34
Trial Phases
5 Phases
Phase 1:64
Phase 2:29
Phase 3:40
+2 more phases
Drug Approvals
26
FDA:20
CANADA:2
PHILIPPINES:2
Drug Approvals
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (156 trials with phase data)• Click on a phase to view related trials
Phase 1
64 (41.0%)Phase 3
40 (25.6%)Phase 2
29 (18.6%)Not Applicable
21 (13.5%)Phase 4
2 (1.3%)Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
Not Applicable
Not yet recruiting
- Conditions
- Infections
- Interventions
- Drug: Meropenem-Pralubactam
- First Posted Date
- 2025-08-15
- Last Posted Date
- 2025-08-15
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT07124468
Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer
Not Applicable
Not yet recruiting
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07104110
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
Not Applicable
Recruiting
- Conditions
- Advanced/Metastatic Solid Tumors
- Interventions
- Drug: MHB088C for Injection
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 515
- Registration Number
- NCT07102004
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Not Applicable
Recruiting
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP)Ventilator-associated Bacterial Pneumonia (VABP)Complicated Intra-abdominal Infection (cIAI)Complicated Urinary Tract Infection (cUTI)Bloodstream Infection (BSI)
- Interventions
- Drug: Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- First Posted Date
- 2025-07-28
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT07089186
- Locations
- 🇨🇳
Huashan Hospital, Fudan Universit, Shanghai, China
To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.
Not Applicable
Recruiting
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Drug: QLM2010 for injection；dexamethasone
- First Posted Date
- 2025-07-23
- Last Posted Date
- 2025-07-28
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 664
- Registration Number
- NCT07081256
- Locations
- 🇨🇳
Zhe jiangCancer Hospital, Hangzhou, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 29
- Next
News
No news found